Skip to main content

22-05-2018 | Non-small-cell lung cancer | Main feed | News


Atezolizumab receives NICE recommendation for NSCLC

medwireNews: The UK’s NHS oncologists may now prescribe atezolizumab as a second-line or later treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).

The National Institute for Health and Care Excellence (NICE) decision pertains to patients who have already completed chemotherapy or appropriate targeted therapy for those with an EGFR or ALK aberration.

Treatment with atezolizumab should continue for 2 years or until disease progresses and will be available at an agreed discount cost via the patient access scheme.

NICE decisions awaited for atezolizumab indications include the treatment of metastatic urothelial cancer after platinum-based chemotherapy or alongside gemcitabine and carboplatin, and in patients with treatment-naïve locally advanced or metastatic renal cell carcinoma.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also

Related topics